Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 69

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 69
---
 allow for manufacture of large, “off-the-shelf” banks of therapeutic cells that could be accessed
on demand by health care professionals to potentially decrease the time between diagnosis and treatment.

In addition, because we focus on
cells from donors, the strategy could potentially enhance the ability of the therapeutic candidates to induce a more robust response once
injected into patients. The human immune system is designed to recognize and distinguish “self” from “non-self”
and destroy “otherness” such as bacteria, viruses, and damaged or diseased cells such as cancer cells. Alloreactivity (reacting
against another person’s cells) is the most powerful response the immune system generates. Several of our technologies take advantage
of the alloreactivity to hyper stimulate a person’s immune response to better attack a chronic infection (e.g., HIV) or solid tumor.

In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are sometimes genetically modified to introduce signaling molecules that are designed to
enhance the ability of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or
virus infected cells.

We believe that the combination
of off-the-shelf allogeneic cells, combined with genetic modifications designed to enhance immune signaling, could potentially generate
therapeutic candidates that have unique attributes that will increase the likelihood of clinical success.

HBV Gene Therapy

Renovaro Biosciences is exploring
various approaches for gene therapy design elements to potentially eliminate virus-infected cells with an innovative molecular mechanism
that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection to exacerbate
disease.

Oncology:

RENB-DC11: Genetically modified Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Solid Tumors – Starting with Pancreatic Cancer

Allogeneic Cell Therapy Platform – Advanced Pre-Clinical

Based
on learnings from literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation, we have
designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission from some of the
deadliest solid tumors. The survival rate in pancreatic cancer is currently only 5 to 10 percent at 5 years.

Initial
preclinical in vitro and proof of concept in vivo studies have been compelling. The platform is designed to enable broad
immune enhancements that are combined with cancer